Fig. 3

The multi-omics feature of mtCN in 663 ESCC paired tumor-normal samples. a The sequencing coverage of mtDNA and nDNA in the 1326 patients. The correlations were evaluated by the Pearson test. b The mtCN in normal and tumor samples. Lines colored in blue indicate a lower mtCN in the tumor over the paired normal samples, otherwise in purple. The p-value was calculated by the two-sided t-test. c The Spearman correlation between the expression of the mtDNA coding genes with mtCN in the tumor, normal, and all samples. d The Spearman correlation between the methylation level of the mtDNA regions with mtCN in the tumor, normal, and all samples. e Plots of overall survival for ESCC patients with mtCN above and below the median value. f Plots of overall survival for ESCC patients with TN-ratio above and below 1. For both e and f, the shaded areas represent the 95% confidence intervals, with the risk table under the survival plot. p values were calculated by log-rank test. g The TN-ratio and mtCN under different T stages. The pairwise comparison was performed by the Wilcox test (* < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001, ns not significant), and the overall p values were calculated by the one-way ANOVA test. h The differentially expressed genes of the tumor samples of patients with TN-ratio > 1 over those with TN-ratio < 1. p values were calculated by the Wilcox test and adjusted by the Bonferroni method. i, j The enriched GO terms of genes significantly (p < 0.01) upregulated (i) and downregulated (j) in the tumor samples of patients with TN-ratio > 1. The p values were adjusted by the Bonferroni method